SCHEMBL25793333

SCHEMBL25793333

COC(=O)c1c(C=O)c2c(Br)c(Cl)ccc2n1CCCOc1cc(S)cc2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARK3 P27448 3/20 0.39
GSK3B P49841 3/20 0.39
CAMK2B Q13554 3/20 0.39
MARK2 Q7KZI7 3/20 0.39
MINK1 Q8N4C8 3/20 0.39
SRPK1 Q96SB4 3/20 0.39
HIPK2 Q9H2X6 3/20 0.39
SYK P43405 2/20 0.39
PLK1 P53350 2/20 0.39
PLK3 Q9H4B4 2/20 0.39
CDC7 O00311 2/20 0.39
IRAK1 P51617 2/20 0.39
NEK4 P51957 2/20 0.39
MAP4K2 Q12851 2/20 0.39
CDC42BPA Q5VT25 2/20 0.39
TAOK1 Q7L7X3 2/20 0.39
HIPK4 Q8NE63 2/20 0.39
MAP3K20 Q9NYL2 2/20 0.39
AURKB Q96GD4 1/20 0.39
PBK Q96KB5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25786217 0.91 MARK3 (0.41) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL25793344 0.86 MARK3 (0.37) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL25250674 0.84 SIRT2 (0.35) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL25786236 0.81 MARK3 (0.35) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL2204536 0.78 MARK3 (0.51) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL25786221 0.77 MARK3 (0.39) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL25251553 0.75 TP53 (0.36) ALDH1A1MAPTKDM4EHPGD
SCHEMBL25786167 0.74 MARK3 (0.41) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL23000228 0.74 MARK3 (0.37) MARK3GSK3BCAMK2BMARK2MINK1
SCHEMBL28371732 0.74 MARK3 (0.37) MARK3GSK3BCAMK2BMARK2MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691989-B2 Macrocyclic indoles as Mcl-1 inhibitors ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691989-B2 Macrocyclic indoles as Mcl-1 inhibitors MCL1, BCL2A1, BCL2L1 MARK3 1429/4885GSK3B 476/4885CAMK2B 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.